The regulation of iron metabolism by hepcidin contributes to unloading-induced bone loss

Bone. 2017 Jan:94:152-161. doi: 10.1016/j.bone.2016.09.023. Epub 2016 Sep 28.

Abstract

Iron overload inhibits osteoblast function and promotes osteoclastogenesis. Hepcidin plays an important role in this process. The changes in iron content and the regulation of hepcidin under unloading-induced bone loss remain unknown. A hindlimb suspension model was adopted to simulate unloading-induced bone loss in mice. The results showed that iron deposition in both liver and bone was markedly increased in hindlimb unloaded mice, and was accompanied by the upregulation of osteoclast activity and downregulation of osteoblast activity. The iron chelator deferoxamine mesylate (DFO) reduced the iron content in bone and alleviated unloading-induced bone loss. The increased iron content in bone was mainly a result of the upregulation of transferrin receptor 1 (TfR1) and divalent metal transporter 1 with iron response element (DMT1+IRE), rather than changes in the iron transporter ferroportin 1 (FPN1). The hepcidin level in the liver was significantly higher, while the FPN1 level in the duodenum was substantially reduced. However, there were no changes in the FPN1 level in bone tissue. During hindlimb unloading, downregulation of hepcidin by siRNA increased iron uptake in bone and liver, which aggravated unloading-induced bone loss. In summary, these data show that unloading-induced bone loss was orchestrated by iron overload and coupled with the regulation of hepcidin by the liver.

Keywords: Bone loss; Hepcidin; Iron; Osteoblast; Osteoclast.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Absorption, Physiological / drug effects
  • Animals
  • Bone Resorption / drug therapy
  • Bone Resorption / etiology*
  • Bone Resorption / metabolism*
  • Bone Resorption / pathology
  • Bone and Bones / metabolism
  • Deferoxamine / pharmacology
  • Deferoxamine / therapeutic use
  • Down-Regulation / drug effects
  • Gene Silencing / drug effects
  • Hepcidins / metabolism*
  • Hindlimb Suspension / adverse effects*
  • Iron / metabolism*
  • Iron Chelating Agents / pharmacology
  • Iron Chelating Agents / therapeutic use
  • Iron Overload / complications
  • Iron Overload / metabolism
  • Liver / metabolism
  • Male
  • Mice, Inbred C57BL
  • RNA, Small Interfering / metabolism
  • Up-Regulation / drug effects

Substances

  • Hepcidins
  • Iron Chelating Agents
  • RNA, Small Interfering
  • Iron
  • Deferoxamine